The widening loss and cash burn are expected for a pre-commercial biotech, but the stock will trade on the PDUFA date (July 7, 2026) and PIONEER Phase 2 data (expected Q2 2026). Monitor for any FDA advisory committee meeting announcement or label expansion data.
Price Chart
Executive Summary
Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per share, wider than the $0.81 loss in Q1 2025, driven by increased R&D and G&A spending ahead of a potential atacicept launch. The company maintains a strong cash position of $596.8M and is on track for a mid-2026 U.S. commercial launch pending FDA approval by July 7, 2026.
Key Financial Metrics
Key Facts
- Net loss per diluted share of $1.69 for Q1 2026 vs $0.81 in Q1 2025
- Cash, cash equivalents, and marketable securities of $596.8M as of March 31, 2026
- FDA PDUFA target action date for atacicept BLA is July 7, 2026
- Company expects U.S. commercial launch of atacicept in mid-2026, pending approval
- Net cash used in operating activities was $106.5M in Q1 2026 vs $54.4M in Q1 2025
Financial Impact
Net loss widened to $121.0M from $51.7M YoY; cash burn increased to $106.5M from $54.4M
Risk Factors
- FDA non-approval or delay of atacicept BLA
- Higher-than-expected cash burn rate could require additional financing
- Competitive landscape in IgA nephropathy
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210351 |
| Document: vera-20260507.htm | 0001193125-26-210351 |
| Document: 0001193125-26-210351-index-headers.html | 0001193125-26-210351 |
| Document: 0001193125-26-210351-index.html | 0001193125-26-210351 |
| Document: 0001193125-26-210351.txt | 0001193125-26-210351 |
| 8-K Data (Synthetic) | 0001193125-26-210351 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $33.67 $34.00 | ▲ +0.98% | ▲ +0.16% | $30.13 (−10.53%) |
Aug 10, 2026 7w ago | 8-K | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Aug 10, 2026 7w ago | Press Release | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Jul 9, 2026 12w ago | 8-K | $42.45 $39.12 | ▼ −7.84% | ▼ −7.71% | $30.13 (−29.03%) |
Jul 7, 2026 12w ago | 8-K | $42.96 $43.13 | ▲ +0.40% | ▼ −0.16% | $30.13 (−29.88%) |
Jun 11, 2026 16w ago | Institutional Cluster | $33.65 $35.01 | ▲ +4.04% | ▲ +3.61% | $30.13 (−10.48%) |
Jun 2, 2026 17w ago | 8-K | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
Jun 2, 2026 17w ago | Press Release | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
May 7, 2026 21w ago | 8-K | $35.88 $39.15 | ▲ +9.11% | ▲ +7.61% | $30.13 (−16.04%) |
Feb 26, 2026 31w ago | 8-K | $42.35 $38.85 | ▼ −8.26% | ▼ −7.14% | $30.13 (−28.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access